trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast']
in this practice changing trial involving patients with her2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician s choice of chemotherapy. #asco22 
Physician, Precision Oncology, Researcher,  Cancer Expert, CEO Protean Biodiagnostics. Professor Oncology and Pathology.